Vanderbilt-Ingram Cancer Center

Dr. Brian I. Rini

Claim this profile

Vanderbilt University/Ingram Cancer Center

Studies Kidney Cancer
Studies Renal Cell Carcinoma
9 reported clinical trials
15 drugs studied

Area of expertise

1

Kidney Cancer

Brian I. Rini has run 7 trials for Kidney Cancer. Some of their research focus areas include:

Stage IV
Stage III
SETD2 positive
2

Renal Cell Carcinoma

Brian I. Rini has run 5 trials for Renal Cell Carcinoma. Some of their research focus areas include:

Stage IV
Stage III
SETD2 positive

Affiliated Hospitals

Image of trial facility.

Vanderbilt University/Ingram Cancer Center

Image of trial facility.

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Clinical Trials Brian I. Rini is currently running

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Image of trial facility.

cfDNA Assay

for Cancer Detection

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.

Recruiting

1 award

N/A

3 criteria

More about Brian I. Rini

Clinical Trial Related

7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Brian I. Rini has experience with

  • Ipilimumab
  • Nivolumab
  • Cabozantinib
  • Anti-OX40 Antibody PF-04518600
  • Axitinib
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Brian I. Rini specialize in?

Is Brian I. Rini currently recruiting for clinical trials?

Are there any treatments that Brian I. Rini has studied deeply?

What is the best way to schedule an appointment with Brian I. Rini?

What is the office address of Brian I. Rini?

Is there any support for travel costs?